Compare KEQU & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | XGN |
|---|---|---|
| Founded | 1906 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.2M | 110.7M |
| IPO Year | 1995 | 2014 |
| Metric | KEQU | XGN |
|---|---|---|
| Price | $33.72 | $7.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.57 |
| AVG Volume (30 Days) | 4.0K | ★ 370.8K |
| Earning Date | 12-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | $11.02 |
| Revenue Next Year | N/A | $10.28 |
| P/E Ratio | $58.21 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $32.00 | $2.59 |
| 52 Week High | $43.36 | $9.74 |
| Indicator | KEQU | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 43.68 |
| Support Level | $33.49 | $6.94 |
| Resistance Level | $38.25 | $7.10 |
| Average True Range (ATR) | 1.11 | 0.70 |
| MACD | 0.17 | -0.16 |
| Stochastic Oscillator | 27.84 | 43.57 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.